TIL Instil Bio Inc
Price (delayed)
$18.32
Market cap
$119.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$11.39
Enterprise value
$194.12M
Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous TIL therapies for the treatment of patients with cancer.
Highlights
TIL's EPS has surged by 53% year-on-year
TIL's net income has soared by 53% YoY
The company's equity fell by 25% YoY and by 3.9% QoQ
Key stats
What are the main financial stats of TIL
Market
Valuations
Earnings
Shares outstanding
6.53M
Market cap
$119.55M
Enterprise value
$194.12M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.71
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$73.54M
Net income
-$74.14M
EBIT
-$65.14M
EBITDA
-$61.32M
Free cash flow
-$55.7M
Per share
Balance sheet
Liquidity
EPS
-$11.39
EPS diluted
-$11.39
Free cash flow per share
-$8.56
Book value per share
$25.96
Revenue per share
$0
TBVPS
$40.49
Total assets
$263.57M
Total liabilities
$94.13M
Debt
$85.2M
Equity
$169.44M
Working capital
$116.57M
Debt to equity
0.5
Current ratio
15.76
Quick ratio
14.58
Net debt/EBITDA
-1.22
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-26.1%
Return on equity
-39.7%
Return on invested capital
-18.6%
Return on capital employed
-25.5%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TIL stock price
How has the Instil Bio stock price performed over time
Intraday
7.64%
1 week
1.83%
1 month
-8.86%
1 year
74.48%
YTD
-4.03%
QTD
5.53%
Financial performance
How have Instil Bio's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$73.54M
Net income
-$74.14M
Gross margin
N/A
Net margin
N/A
The operating income has soared by 54% YoY
TIL's net income has soared by 53% YoY
Growth
What is Instil Bio's growth rate over time
Valuation
What is Instil Bio stock price valuation
P/E
N/A
P/B
0.71
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TIL's EPS has surged by 53% year-on-year
TIL's price to book (P/B) is 61% lower than its 5-year quarterly average of 1.7 and 34% lower than its last 4 quarters average of 1.0
The company's equity fell by 25% YoY and by 3.9% QoQ
Efficiency
How efficient is Instil Bio business performance
TIL's ROIC is up by 48% year-on-year
Instil Bio's return on assets has increased by 37% YoY but it has decreased by 4% QoQ
The return on equity rose by 32% year-on-year but it has declined by 6% since the previous quarter
Dividends
What is TIL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TIL.
Financial health
How did Instil Bio financials performed over time
TIL's total assets is 180% greater than its total liabilities
Instil Bio's quick ratio has increased by 25% QoQ
Instil Bio's current ratio has increased by 22% QoQ and by 3.5% YoY
Instil Bio's debt is 50% less than its equity
The debt to equity has grown by 35% YoY and by 6% from the previous quarter
The company's equity fell by 25% YoY and by 3.9% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.